Financial Performance Overview
Bal Pharma Limited reported mixed financial results for FY 2025-26, with standalone revenue increasing 3% to ₹312.80 crore (₹304.65 crore in FY25) while net profit declined 13% to ₹6.75 crore (₹7.80 crore in FY25). Consolidated performance showed similar trends with total income of ₹313.59 crore and net profit of ₹6.32 crore. The company maintained a balanced revenue mix with exports contributing 63% of total revenue and domestic sales 37%, split equally between API and formulations businesses.
Operational Highlights and Challenges
The company suspended operations at its loss-making Pune IV fluids and parenterals manufacturing facility due to consistent operational losses from higher raw material costs, production cost escalation, and thin margins. Management is considering disinvestment or partnership options to exit this non-core business. On the positive side, the company completed major Schedule M compliance projects across manufacturing facilities and renewed European regulatory approvals for Units II and IV.
Capital Structure and Financial Position
Total borrowings increased to ₹15,374.79 lakhs with a debt-equity ratio of 1.48, while the company maintained a current ratio of 1.05. Net worth stood at ₹104.10 crore, up from ₹98.82 crore in FY25. The company maintained significant foreign exchange exposure with net assets of ₹3,284.29 lakhs in foreign currencies, primarily USD (87%) and EUR (11%).
Corporate Actions and Governance
The Board recommended a dividend of ₹1.20 per equity share (12% on face value) for FY 2025-26, involving an outflow of approximately ₹1.91 crore. Significant board changes occurred including the appointment of Mr. Ravindra Kumar Kothari as Additional Director and his proposed designation change from Non-Executive to Whole-Time Director effective October 1, 2026, with remuneration of ₹22.50 lakh per annum. Mr. Virupakshaya Himesh is proposed to change from Whole-Time Director to Non-Executive Director with honorarium of ₹2.40 lakh per annum.
Subsidiaries and Related Party Transactions
The company has four subsidiaries: Lifezen Healthcare Private Limited (99.40% ownership), Bal Research Foundation (80% ownership), Balance Clinics LLP (80% ownership), and Aurum Research & Analytical Solutions Private Limited (95% ownership). The company renewed its contract with Desa Marketing International (related party) for marketing services with a commission structure of 2% on domestic and 3% on international sourcing/marketing, with an aggregate limit of ₹30 crore per financial year.
Regulatory Compliance and Audit Matters
The company experienced temporary non-compliance with SEBI board composition requirements during Q3 FY26 (43 days), resulting in fines paid to BSE and NSE. Auditors S S J N B & CO issued an unqualified opinion, with key audit matters focusing on related party transactions identification, inventory valuation, and contingencies including litigations and tax.
Forward Outlook
Management expects improved performance in FY 2026-27 due to completion of Schedule M compliance projects, better operational efficiencies, increased capacity utilization, growth in regulated export markets, and expansion of value-added API products. The company maintains a BBB- stable credit rating by Acute and operates 6 manufacturing units across India with 939 permanent employees.